Net Cash Provided by (Used in) Financing Activities of BriaCell Therapeutics Corp. from 31 Jul 2021 to 31 Jul 2025

Taxonomy & unit
us-gaap: USD
Description
Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit.
Summary
BriaCell Therapeutics Corp. annual and quarterly Net Cash Provided by (Used in) Financing Activities in USD history and change rate from 31 Jul 2021 to 31 Jul 2025.
  • BriaCell Therapeutics Corp. Net Cash Provided by (Used in) Financing Activities for the quarter ending 31 Oct 2024 was $11,960,252.
  • BriaCell Therapeutics Corp. annual Net Cash Provided by (Used in) Financing Activities for 2025 was $45,448,239, a 928% increase from 2024.
  • BriaCell Therapeutics Corp. annual Net Cash Provided by (Used in) Financing Activities for 2024 was $4,418,926, a 12% increase from 2023.
  • BriaCell Therapeutics Corp. annual Net Cash Provided by (Used in) Financing Activities for 2023 was $3,954,300.
Source SEC data
View on sec.gov
Net Cash Provided by (Used in) Financing Activities, Annual (USD)
Net Cash Provided by (Used in) Financing Activities, YoY Annual Change (%)
Net Cash Provided by (Used in) Financing Activities, Quarterly (USD)

BriaCell Therapeutics Corp. Annual Net Cash Provided by (Used in) Financing Activities (USD)

Period Value YoY Chg Change % Start Date End Date Report Filed Fiscal Year Fiscal Period
2025 $45,448,239 +$41,029,313 +928% 01 Aug 2024 31 Jul 2025 10-K 16 Oct 2025 2025 FY
2024 $4,418,926 +$464,626 +12% 01 Aug 2023 31 Jul 2024 10-K 16 Oct 2025 2025 FY
2023 $3,954,300 +$7,696,957 01 Aug 2022 31 Jul 2023 10-K 29 Oct 2024 2024 FY
2022 $3,742,657 -$68,740,281 -106% 01 Aug 2021 31 Jul 2022 10-K 25 Oct 2023 2023 FY
2021 $64,997,624 01 Aug 2020 31 Jul 2021 10-K 28 Oct 2022 2022 FY

BriaCell Therapeutics Corp. Quarterly Net Cash Provided by (Used in) Financing Activities (USD)

Period TTM Value Value YoY Chg Change % Start Date End Date Report Filed Fiscal Year Fiscal Period
Q3 2024 $11,960,252 01 Aug 2024 31 Oct 2024 10-Q 11 Dec 2025 2026 Q1
Q3 2022 $47,294 01 Aug 2022 31 Oct 2022 10-Q 14 Dec 2023 2024 Q1
* An asterisk sign (*) next to the value indicates that the value is likely invalid.